Previous studies reported that IKK/NF-κB inhibition can help promote bone formation in the treatment of osteoporosis and bone diseases.39 NF-κB is central to the regulation of PDLSC osteogenic differentiation in inflammatory microenvironments.40 LPS can trigger NF-κB activation and facilitate p65/p50 translocation into nucleus, where it activates the transcription of NF-κB.41 The nuclear translocation of NF-κB was detected in cells cultured with MM+LPS, whereas p-NF-κB and LC3 were colocalized in the cytoplasm. This evidence concerns the gene NFKB1 and osteoporosis.